Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30,284,111
-
Number of holders
-
86
-
Total 13F shares, excl. options
-
13,732,777
-
Shares change
-
-274,920
-
Total reported value, excl. options
-
$543,300,250
-
Value change
-
-$15,835,150
-
Number of buys
-
41
-
Number of sells
-
-34
-
Price
-
$39.56
Significant Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q3 2021
95 filings reported holding KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q3 2021.
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) has 86 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13,732,777 shares
of 30,284,111 outstanding shares and own 45.35% of the company stock.
Largest 10 shareholders include FMR LLC (3,500,679 shares), ORBIMED ADVISORS LLC (1,679,417 shares), BlackRock Inc. (1,234,158 shares), Nantahala Capital Management, LLC (760,383 shares), VANGUARD GROUP INC (709,761 shares), ALKEON CAPITAL MANAGEMENT LLC (701,433 shares), STATE STREET CORP (677,268 shares), FRANKLIN RESOURCES INC (394,660 shares), Opaleye Management Inc. (352,500 shares), and Clal Insurance Enterprises Holdings Ltd (311,135 shares).
This table shows the top 86 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.